000			03377nam a22002897a 4500
001			20241102135253.0
003			OCoLC
005			20241102135759.0
008			241102b |||||||| |||| 00| 0 eng d
010			_a2018957321
020			_a 978-3-319-96988-6
020			_a978-3-319-96989-3 (eBook)
040			_cddc
041			_aEnglish
100			_qGabriel G. Malouf
222			_aadults anaplasia associated bevacizumab bilateral ccRCC CDC patients cell RCC cell renal cell characterized chemotherapy Children's Oncology Group ChRCC chromophobe chromophobe renal cell chromosome clear cell renal clear-cell Clin Oncol COG collecting duct collecting duct carcinoma cytogenetic diagnosis differentiation doxorubicin epithelial everolimus fusion transcripts gemcitabine gene genetic genomic germline mutations grade histologic histologic subtype HLRCC HPRC imaging immunohistochemical kidney cancer lesions lung lymph node malignancies Malouf median metastasectomy metastatic metastatic disease molecular non-clear cell outcome papillary RCC papillary renal cell Pathology pathway patients with metastatic Pediatr phase pRCC prognostic factors RCC renal carcinoma renal cell carcinoma renal masses renal medullary carcinoma renal tumors reported resection risk RMC sarcomatoid component sarcomatoid renal cell sickle cell SIOP SMARCB1 sorafenib sporadic sRCC stage sunitinib Surg Pathol surgery surgical syndrome Tannir targeted therapy TFE3 TFEB translocation renal cell tRCC treatment tumor suppressor Urol VHL Wilms tumor WT XRT
240			_aRare Kidney Tumors
245			_a Rare Kidney Tumors _bComprehensive Multidisciplinary Management and Emerging Therapies.
260			_aDepartment of Hematology and Oncology Strasbourg University Hospital Hopital Civil Strasbourg France | _bSpringer Nature Switzerland AG | _c 2019.
300			_a131 Pages
300			_aIncludes References
520			_aThis book provides clinicians with clear guidance on treatment decision-making in patients with rare kidney cancers. After a brief review on epidemiology, pathology, and biology, each chapter focuses on the multidisciplinary management of a particular tumor subtype using the full range of available cancer therapy modalities, including surgery, radiotherapy, chemotherapy, targeted therapies, and immunotherapy. Emerging therapies and future directions in the management of each cancer subtype are also discussed. The chapters are all written by multidisciplinary teams of international experts comprising at least a urologist, a medical oncologist, and a pathologist. Rare kidney cancers represent 15% of renal cell carcinomas. In comparison with clear cell renal cell carcinomas, little is known about the biology of such cancers, and few trials have reported on the efficacy of targeted therapies in the metastatic setting. Optimal management thus poses significant challenges and often requires a multidisciplinary team. This book will be an ideal reference guide for all clinicians involved in the care of patients with these orphan tumors.
600			_x Medical / Clinical Medicine, Medical / Oncology / General, Medical / Pediatrics, Medical / Urology, Oncology, Pediatrics, Urology, Kidneys -- Cancer -- Diseases, Medicine.
700			_qNizar M. Tannir
856			_uhttps://doi.org/10.1007/978-3-319-96989-3
942			_2ddc _cEB _n0
999			_c29570 _d29570